Type I interferons mediate pancreatic toxicities of PERK inhibition.

导出 OA

翻译打印收藏纠错

作者： Qiujing,Yu ^[1] ; Bin,Zhao ^[1] ; Jun,Gui ^[1] ; Kanstantsin V,Katlinski ^[1] ; Angela,Brice ^[2] ; Yan,Gao ^[3] ; ChangHong,Li ^[4] ; Jake A,Kushner ^[5] ; Constantinos,Koumenis ^[6] ; J Alan,Diehl ^[3] ; Serge Y,Fuchs ^[7]

作者单位： Department of Animal Biology, School of Veterinary Medicine, Philadelphia, PA 19104; ^[1] Department of Pathobiology, School of Veterinary Medicine, Philadelphia, PA 19104; ^[2] Department of Biochemistry, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425; ^[3] Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104; ^[4] McNair Medical Institute, Pediatric Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030; ^[5] Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. ^[6] Department of Animal Biology, School of Veterinary Medicine, Philadelphia, PA 19104; syfuchs@vet.upenn.edu. ^[7]

关键词 PERK Wolcott-Rallison syndrome diabetes interferon pancreas